Previous 10 | Next 10 |
ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on Monday, May 17, 2021, at ...
Aytu BioPharma (AYTU) announces the acquisition of a global license to AR101 (enzastaurin) from Rumpus Therapeutics, a privately-held biopharmaceutical company focused on the treatment of pediatric onset rare and orphan diseases.AR101 (enzastaurin) is a pivotal study-ready therapeutic ca...
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue disorder resulting in high...
Aytu BioPharma (AYTU) appoints Richard Eisenstadt as Chief Financial Officer ((CFO)), replacing David Green who stepped down as of March 31, 2021. Most recently, Mr. Eisenstadt was CFO at Neos Therapeutics, where he raised over $340M in private and public equity and debt financings ...
ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer. Mr. Eisenstadt...
Aytu BioPharma ([[AYTU]] -1.0%) announced an agreement with Acerus Pharmaceuticals Corporation to divest all remaining rights to Natesto in the U.S. for $7.5M.With a 120-day transition period, Aytu will transfer all product responsibilities linked to Natesto to Acerus effective April 1, 2021....
Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO / ACCESSWIRE / April 1, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focuse...
Oppenheimer is downgrading shares of Ascendis Pharma (ASND) from outperform to perform and removing its $212 price target.Analyst Leland Gershell says that Street estimates for sales of TransCon hGH (lonapegsomatropin) for pediatric growth hormone deficiency, a BLA for which was submitted las...
Frequency Therapeutics (FREQ) -71% after releases new data. from two FX-322 clinical studies; plans to advance single-dose regimen.Anixa Biosciences (ANIX) -23% after raises previously announced bought deal offering of common stock to $22.5M.Windtree Therapeutics (WIN...
Merger activity remained steady last week. Two of the largest deals of this year were announced last week. SPAC activity continues to grow at a steady pace. For further details see: Merger Arbitrage Mondays - Coherent Shareholders Delighted By Another Round Of Counteroff...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...